

Special Issue

Vaccination or Infection and the Role of T Cells—The Response to Cancer, Autoimmunity or Inflammatory Diseases

Message from the Guest Editor

The roles of T cells in cancer, autoimmune, and inflammatory diseases represent an area of rapidly advancing research, providing crucial insights into immune regulation and disease development. T cells play a key role in regulating immune responses and orchestrating immune reactions through their various subpopulations and adaptable functions. In cancer, T cells can promote anti-tumor immunity, but they can also contribute to tumor immune evasion and resistance to immunotherapy. In autoimmune and inflammatory diseases, imbalanced T-cell responses can lead to persistent inflammation and tissue damage.

Understanding the mechanisms behind T-cell function and dysfunction is critical for developing targeted therapies that regulate T-cell activity, offering promising approaches for treating a range of diseases. For this Special Issue, we request original research, reviews, and studies that deepen our understanding of T-cell biology, their roles in disease, and innovative therapeutic strategies targeting T cells.

Guest Editor

Prof. Dr. Yuedan Wang

NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China

Deadline for manuscript submissions

30 June 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/207338

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).